The specific price of a box of Tofacitinib in 2025

Tofacitinib, an oral JAK inhibitor, plays an increasingly critical role in the long-term management of autoimmune diseases. It can block multiple inflammatory factor signaling pathways and reduce the excessive activation of inflammatory cells from the source. Therefore, it is widely used in the long-term systemic treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis and other diseases. With the acceleration of research on the JAK signaling pathway at home and abroad in recent years, tofacitinib is regarded by more and more patients as an oral alternative that is both convenient and has good compliance, especially for people who cannot tolerate or have poor response to traditional treatments. It provides new possibilities for disease relief.

Domestically, tofacitinib is marketed in the form of tofacitinib citrate tablets and is included in Medicare Category B, allowing patients to maintain efficacy at a more acceptable cost during long-term treatment. After reimbursement by medical insurance, the price of tofacitinib varies according to specific specifications and hospital implementation standards, usually ranging from tens to hundreds of yuan, and the overall burden has dropped significantly. In overseas markets, some countries and regions allow the sale of generic versions. Among them, generic drugs produced in Bangladesh are well-known. The price per box is usually around 200 yuan, but the specific price will still fluctuate due to exchange rate changes.

It is worth noting thatThe consistency of the core ingredients of "original research and generic" allows patients to flexibly adjust according to doctor's recommendations and financial affordability when making choices. Doses of different specifications, whether it is a sustained-release preparation, and whether it belongs to the hospital's self-pay or medical insurance catalog varieties will cause differences in prices. Taken together, whether it is the domestic original version or the overseas generic version, tofacitinib is gradually moving towards a price range that more patients can accept in the long term.

Reference materials:https://www.xeljanz.com/